

Gloria S Huang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2395278/publications.pdf>

Version: 2024-02-01

96
papers

2,124
citations

201674

27
h-index

254184

43
g-index

97
all docs

97
docs citations

97
times ranked

3584
citing authors

#	ARTICLE	IF	CITATIONS
1	Randomised phase II trial of weekly ixabepilone±biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer. <i>British Journal of Cancer</i> , 2022, 126, 1695-1703.	6.4	5
2	A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability. <i>Cancer</i> , 2022, 128, 1206-1218.	4.1	28
3	Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor. <i>Gynecologic Oncology</i> , 2022, 166, 117-125.	1.4	12
4	High-risk Endometrial Cancer: The Present and Future of Adjuvant Therapy. <i>Touch Reviews in Oncology & Haematology</i> , 2021, 17, 23.	0.2	0
5	Financial toxicity in patients with gynecologic malignancies: a cross sectional study. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e87.	2.2	10
6	Sex Hormones, Insulin, and Insulin-like Growth Factors in Recurrence of High-Stage Endometrial Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 719-726.	2.5	6
7	Integrated mutational landscape analysis of uterine leiomyosarcomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	48
8	DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo. <i>Gynecologic Oncology</i> , 2021, 163, 334-341.	1.4	10
9	Randomized phase II trial of weekly ixabepilone with or without biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer. <i>Gynecologic Oncology</i> , 2021, 162, S58.	1.4	4
10	Charlson Comorbidity Index as a predictor of postoperative complication in octogenarians and nonagenarians with stage I endometrioid endometrial cancer: a single-institution retrospective review. <i>Gynecologic Oncology</i> , 2021, 162, S108.	1.4	0
11	Trastuzumab tolerability in the treatment of advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress HER2/neu. <i>Gynecologic Oncology</i> , 2021, 163, 93-99.	1.4	14
12	In vitro and in vivo activity of DHES0815A, an antibody-drug conjugate targeting HER2/neu in uterine serous carcinoma. <i>Gynecologic Oncology</i> , 2021, 162, S186-S187.	1.4	0
13	Financial toxicity in patients with gynecologic malignancies. <i>Gynecologic Oncology</i> , 2021, 162, S162.	1.4	0
14	Prognostic impact of mismatch repair deficiency in high- and low-intermediate-risk, early-stage endometrial cancer following vaginal brachytherapy. <i>Gynecologic Oncology</i> , 2021, 163, 557-562.	1.4	4
15	Sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo. <i>Molecular Oncology</i> , 2020, 14, 645-656.	4.6	20
16	In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma. <i>Gynecologic Oncology</i> , 2020, 156, 430-438.	1.4	18
17	Population-Based Screening for Endometrial Cancer: Human vs. Machine Intelligence. <i>Frontiers in Artificial Intelligence</i> , 2020, 3, 539879.	3.4	17
18	Prescribed medical cannabis in women with gynecologic malignancies: A single-institution survey-based study. <i>Gynecologic Oncology Reports</i> , 2020, 34, 100667.	0.6	8

#	ARTICLE	IF	CITATIONS
19	Derangements in HUWE1/c-MYC pathway confer sensitivity to the BET bromodomain inhibitor GS-626510 in uterine cervical carcinoma. <i>Gynecologic Oncology</i> , 2020, 158, 769-775.	1.4	2
20	Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan. <i>Scientific Reports</i> , 2020, 10, 973.	3.3	31
21	Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas. <i>Oncotarget</i> , 2020, 11, 560-570.	1.8	32
22	Abstract 4851: Combination of letrozole plus abemaciclib is synergistic and suppresses tumor growth in ovarian and endometrial cancer models. , 2020, , .		0
23	Stage III uterine serous carcinoma: modern trends in multimodality treatment. <i>Journal of Gynecologic Oncology</i> , 2020, 31, e53.	2.2	1
24	Precision Therapy for Aggressive Endometrial Cancer by Reactivation of Protein Phosphatase 2A. <i>Cancer Research</i> , 2019, 79, 4009-4010.	0.9	4
25	Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 22730-22736.	7.1	52
26	PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib. <i>Gynecologic Oncology</i> , 2019, 155, 144-150.	1.4	28
27	Stratifying Ovarian Cancer Risk Using Personal Health Data. <i>Frontiers in Big Data</i> , 2019, 2, 24.	2.9	8
28	Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 619-624.	7.1	49
29	PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers. <i>Gynecologic Oncology</i> , 2019, 153, 158-164.	1.4	13
30	Neutrophilia and mortality in women with uterine carcinosarcoma. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1258-1263.	2.5	3
31	ARID1A interacts with nonmuscle myosin IIA to regulate cancer cell motility.. <i>Journal of Clinical Oncology</i> , 2019, 37, e17036-e17036.	1.6	0
32	Sex hormone, insulin, and insulin-like growth factor signaling in recurrence of high stage endometrial cancer: Results from the NRG Oncology/Gynecologic Oncology Group 210 trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5509-5509.	1.6	0
33	Insulin-like growth factor 2: a poor prognostic biomarker linked to racial disparity in women with uterine carcinosarcoma. <i>Cancer Medicine</i> , 2018, 7, 616-625.	2.8	5
34	<i>In Vitro</i> and <i>In Vivo</i> Activity of IMGN853, an Antibody-Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1003-1011.	4.1	25
35	Female Sex Hormone Receptor Profiling in Uterine Adenosarcomas. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 500-504.	2.5	6
36	A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma. <i>Gynecologic Oncology</i> , 2018, 149, 585-591.	1.4	53

#	ARTICLE	IF	CITATIONS
37	Evaluation of a Streamlined Oncologist-Led <i>BRCA</i> Mutation Testing and Counseling Model for Patients With Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1300-1307.	1.6	76
38	Impact of carboplatin hypersensitivity and desensitization on patients with recurrent ovarian cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 2449-2456.	2.5	20
39	Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 4845-4853.	7.0	18
40	Genetic landscape of clear cell endometrial cancer and the era of precision medicine. <i>Cancer</i> , 2017, 123, 3216-3218.	4.1	4
41	SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression. <i>Gynecologic Oncology</i> , 2017, 146, 179-186.	1.4	37
42	Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression. <i>Gynecologic Oncology</i> , 2017, 147, 145-152.	1.4	18
43	Assessment of BRCA testing uptake in ovarian cancer patients during the implementation of an oncologist-led genetic counseling model at an urban and suburban teaching hospital.. <i>Journal of Clinical Oncology</i> , 2017, 35, 1589-1589.	1.6	0
44	ENGAGE: Evaluation of a streamlined oncologist-led BRCA mutation (BRCAm) testing and counselling model for patients with ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5559-5559.	1.6	0
45	Retreatment with aromatase inhibitor therapy in the management of granulosa cell tumor. <i>Gynecologic Oncology Reports</i> , 2016, 15, 20-21.	0.6	5
46	Insulin/IGF and sex hormone axes in human endometrium and associations with endometrial cancer risk factors. <i>Cancer Causes and Control</i> , 2016, 27, 737-748.	1.8	34
47	RNA-seq Identification of RACGAP1 as a Metastatic Driver in Uterine Carcinosarcoma. <i>Clinical Cancer Research</i> , 2016, 22, 4676-4686.	7.0	37
48	Evaluation of circulating neutrophils as a biomarker for outcomes in uterine carcinosarcoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, e17121-e17121.	1.6	0
49	Evaluating a novel oncologist-led <i>BRCA1/2</i> mutation (<i>BRCA</i> m) testing counseling model for patients with ovarian cancer: Interim results from the ENGAGE study.. <i>Journal of Clinical Oncology</i> , 2016, 34, e17048-e17048.	1.6	0
50	Evaluation of insulin-like growth factor 2 as a biomarker in uterine carcinosarcoma. <i>Gynecologic Oncology</i> , 2015, 137, 60-61.	1.4	0
51	PTEN expression in benign human endometrial tissue and cancer in relation to endometrial cancer risk factors. <i>Cancer Causes and Control</i> , 2015, 26, 1729-1736.	1.8	31
52	Transforming Growth Factor β 1 and Extracellular Matrix Protease Expression in the Uterosacral Ligaments of Patients With and Without Pelvic Organ Prolapse. <i>Female Pelvic Medicine and Reconstructive Surgery</i> , 2015, 21, 53-58.	1.1	12
53	IGF2 signaling and regulation in cancer. <i>Cytokine and Growth Factor Reviews</i> , 2015, 26, 371-377.	7.2	92
54	Evasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds. <i>Seminars in Cancer Biology</i> , 2015, 35, S55-S77.	9.6	95

#	ARTICLE	IF	CITATIONS
55	Evaluation of a novel combination treatment strategy using patient-derived xenografts of uterine carcinosarcoma. <i>Gynecologic Oncology</i> , 2015, 137, 201-202.	1.4	0
56	The impact of obesity on prostate cancer recurrence observed after exclusion of diabetics. <i>Cancer Causes and Control</i> , 2015, 26, 821-830.	1.8	19
57	Designing a broad-spectrum integrative approach for cancer prevention and treatment. <i>Seminars in Cancer Biology</i> , 2015, 35, S276-S304.	9.6	220
58	Abstract 5257: Immunohistochemical analysis and comprehensive hormone receptor profiling of uterine adenosarcomas at a single institution. , 2015, , .		0
59	Abstract 5131: Establishment of uterine carcinosarcoma primary cell lines for chemosensitivity testing and evaluation of targeted therapy. , 2015, , .		0
60	Insulin-Like Growth Factor 2 Silencing Restores Taxol Sensitivity in Drug Resistant Ovarian Cancer. <i>PLoS ONE</i> , 2014, 9, e100165.	2.5	33
61	Subcellular localization and function of insulin-like growth factor 2 (IGF2) in uterine carcinosarcoma. <i>Gynecologic Oncology</i> , 2014, 133, 111.	1.4	9
62	ER-alpha, PR, EGFR and GPER expression differentially correlate with survival in endometrial carcinoma. <i>Gynecologic Oncology</i> , 2013, 130, e86.	1.4	1
63	Predictors and incidence of radical vulvectomy complications in the modern era: A National Surgical Quality Improvement Program study. <i>Gynecologic Oncology</i> , 2013, 130, e38.	1.4	0
64	Abstract 948: In vivo evaluation of IGF2 RNA interference in a mouse xenograft model of paclitaxel-resistant human ovarian cancer.. , 2013, , .		0
65	RACGAP1 overexpression in uterine carcinosarcomas.. <i>Journal of Clinical Oncology</i> , 2013, 31, e22009-e22009.	1.6	0
66	Phase II trial of adjuvant pelvic radiation "sandwiched" between combination paclitaxel and carboplatin in women with uterine papillary serous carcinoma. <i>Gynecologic Oncology</i> , 2012, 124, 21-25.	1.4	57
67	Phase II trial of adjuvant pelvic radiation "sandwiched" between ifosfamide or ifosfamide plus cisplatin in women with uterine carcinosarcoma. <i>Gynecologic Oncology</i> , 2012, 124, 26-30.	1.4	45
68	Modulation of drug resistance in ovarian carcinoma cells by insulin-like growth factor-2 RNA interference. <i>Gynecologic Oncology</i> , 2012, 125, S135.	1.4	0
69	Abstract 1080: Effect of IGF2 overexpression on the tumorigenicity of human ovarian carcinoma cells. , 2012, , .		2
70	Performance of Serum CA125 as a Prognostic Biomarker in Patients With Uterine Papillary Serous Carcinoma. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 529-534.	2.5	23
71	Antiproliferative activity of a phenolic extract from a native Chilean Amaranthaceae plant in drug-resistant ovarian cancer cell lines. <i>Gynecologic Oncology</i> , 2011, 120, S43.	1.4	1
72	Tumor expression of the type I insulin-like growth factor receptor is an independent prognostic factor in epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2011, 120, S58.	1.4	0

#	ARTICLE	IF	CITATIONS
73	Downregulation of Filamin A Interacting Protein 1-Like is Associated with Promoter Methylation and Induces an Invasive Phenotype in Ovarian Cancer. <i>Molecular Cancer Research</i> , 2011, 9, 1126-1138.	3.4	31
74	Clinical utility of chromogranin a and octreotide in large cell neuro endocrine carcinoma of the uterine corpus. <i>Rare Tumors</i> , 2011, 3, 129-131.	0.6	20
75	Abstract 5020: Potential lifestyle intervention in inner city women with endometrial cancer: A pilot study. , 2011, , .		34
76	Abstract A48: Effect of constitutive IGF2 overexpression on tumorigenicity of human ovarian carcinoma cells. , 2011, , .		0
77	Co-expression of GPR30 and ER β and their association with disease progression in uterine carcinosarcoma. <i>American Journal of Obstetrics and Gynecology</i> , 2010, 203, 242.e1-242.e5.	1.3	31
78	Insulin-like Growth Factor 2 Expression Modulates Taxol Resistance and Is a Candidate Biomarker for Reduced Disease-Free Survival in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 2999-3010.	7.0	85
79	Abstract 1809: Reversal of Taxol resistance in ovarian cancer cell lines by IGF pathway inhibition. , 2010, , .		0
80	Abstract A33: in ovarian cancer cell lines resistant to microtubule-stabilizing agents, expression of IGF2 and ABCB1 is increased and IGF1R inhibition restores drug sensitivity. , 2010, , .		0
81	A phase II study of weekly topotecan and docetaxel in heavily treated patients with recurrent uterine and ovarian cancers. <i>Gynecologic Oncology</i> , 2009, 113, 327-330.	1.4	19
82	Extragenital adenosarcoma: A case report, review of the literature, and management discussion. <i>Gynecologic Oncology</i> , 2009, 115, 472-475.	1.4	28
83	Tissue microarray analysis of hormonal signaling pathways in uterine carcinosarcoma. <i>American Journal of Obstetrics and Gynecology</i> , 2009, 200, 457.e1-457.e5.	1.3	18
84	Survival and toxicity differences between 5-day and weekly cisplatin in patients with locally advanced cervical cancer. <i>Cancer</i> , 2007, 109, 48-53.	4.1	21
85	Serum CA125 predicts extrauterine disease and survival in uterine carcinosarcoma. <i>Gynecologic Oncology</i> , 2007, 107, 513-517.	1.4	61
86	Accuracy of preoperative endometrial sampling for the detection of high-grade endometrial tumors. <i>American Journal of Obstetrics and Gynecology</i> , 2007, 196, 243.e1-243.e5.	1.3	106
87	Potential of Taxol Efficacy by Discodermolide in Ovarian Carcinoma Xenograft-Bearing Mice. <i>Clinical Cancer Research</i> , 2006, 12, 298-304.	7.0	75
88	Consolidation therapy for ovarian cancer. <i>Women's Oncology Review</i> , 2005, 5, 3-8.	0.0	0
89	Total laparoscopic hysterectomy versus total abdominal hysterectomy: cohort review of patients with uterine neoplasia. <i>Journal of the Society of Laparoendoscopic Surgeons</i> , 2005, 9, 277-86.	1.1	30
90	Consolidation therapy for ovarian cancer. <i>Women's Oncology Review</i> , 2005, 5, 3-8.	0.0	0

#	ARTICLE	IF	CITATIONS
91	Selective incorporation of total laparoscopic hysterectomy for adnexal pathology and body mass index. Gynecologic Oncology, 2004, 93, 137-143.	1.4	17
92	Total laparoscopic hysterectomy for oncological indications with outcomes stratified by age. Gynecologic Oncology, 2004, 95, 196-203.	1.4	13
93	Total laparoscopic hysterectomy: body mass index and outcomes. Obstetrics and Gynecology, 2003, 102, 1384-1392.	2.4	64
94	Total Laparoscopic Hysterectomy. Obstetrics and Gynecology, 2003, 102, 1384-1392.	2.4	15
95	Liposomal Doxorubicin for Treatment of Metastatic Chemorefractory Vulvar Adenocarcinoma. Gynecologic Oncology, 2002, 87, 313-318.	1.4	16
96	Site Specificity of Short-Term and Long-Term Habituation in the Tail-Elicited Siphon Withdrawal Reflex of Aplysia. Journal of Neuroscience, 1996, 16, 4923-4932.	3.6	35